SEARCH

SEARCH BY CITATION

References

  • 1
    UNAIDS/WHO. AIDS epidemic update: November 2009. WHO Library Cataloguing-in-Publication Data. 2009.
  • 2
    Rice DB, Batzing-Feigenbaum J, Hosegood V, Tanser F, Hill C, Barnighausen T, et al. Population and antenatal-based HIV prevalence estimates in a high contracepting female population in rural South Africa. BMC Public Health 2007;7:160.
  • 3
    Morrison SC, Wang J, Van Der Pol B, Padian N, Salata AR, Richardson AB. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS 2007;21:102734.
  • 4
    Gray HR, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005;366:11828.
  • 5
    Moodley D, Esterhuizen MT, Pather T, Chetty V, Ngaleka L. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS 2009;23:12559.
  • 6
    Health-Protection-Agency. Populations requiring specific interventions: pregnant women. http://www.hpaorguk . 2009.
  • 7
    Ribeiro SP, Jacobsen HK, Mathers DC, Garcia-Moreno C. Priorities for women’s health from the Global Burden of Disease study. Int J Gynaecol Obstet 2008;102:8290.
  • 8
    WHO. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. WHO Library Cataloguing-in-Publication Data. 2009.
  • 9
    WHO. Antiretroviral drugs for treating pregnant pregnant women and preventing HIV Infections in Infants: recommendations for a public health approach. WHO Library Cataloguing-in-Publication Data. 2010.
  • 10
    UN. United Nations Millennium Declaration. 18 September 2000.
  • 11
    WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009. http://www.who.int/hiv/pub/2009progressreport/en/ . 2009.
  • 12
    Black V, Brooke S, Chersich FM. Effect of human immunodeficiency virus treatment on maternal mortality at a tertiary center in South Africa: a 5-year audit. Obstet Gynecol 2009;114:2929.
  • 13
    Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998;105:83648.
  • 14
    Rollins CN, Coovadia MH, Bland MR, Coutsoudis A, Bennish LM, Patel D, et al. Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South Africa. J Acquir Immune Defic Syndr 2007;44:3218.
  • 15
    Habib AN, Daltveit KA, Bergsjo P, Shao J, Oneko O, Lie TR. Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study. BJOG 2008;115:61624.
  • 16
    Houlihan FC, Bland MR, Mutevedzi CP, Lessells JR, Ndirangu J, Thulare H, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 2010; [Epub ahead of print 12 February 2010].
  • 17
    Herbst JA, Cooke SG, Barnighausen T, KanyKany A, Tanser F, Newell LM. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ 2009;87:75462.
  • 18
    Newell LM, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:123643.
  • 19
    Ndirangu J, Newell LM, Tanser F, Herbst JA, Bland R. Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? AIDS 2010;24:593602.
  • 20
    Ndirangu J. Impact of maternal HIV treatment on under-five child mortality in rural, high HIV prevalence South Africa. 18th International AIDS Conference, Vienna, 2010. abstract MOAE0104.
  • 21
    Thorne C, Patel D, Newell LM. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004;18:23379.
  • 22
    European Collaborative Study (ECS) and the Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14:291320.
  • 23
    Lorenzi P, Spicher MV, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F2417.
  • 24
    European Collbaorative Study (ECS). Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:3807.
  • 25
    Tuomala ER, Shapiro ED, Mofenson ML, Bryson Y, Culnane M, Hughes DM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Eng J Med 2002;346:186370.
  • 26
    Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla LJ, Burgard M, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:208393.
  • 27
    Tuomala ER, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 2006;193:11914.
  • 28
    Martin F, Taylor PG. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 2007;196:55861.
  • 29
    Townsend LC, Cortina-Borja M, Peckham SC, Tookey AP. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007;21:101926.
  • 30
    Cotter MA, Garcia GA, Duthely LM, Luke B, O’Sullivan JM. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006;193:1195201.
  • 31
    Townsend LC, Cortina-Borja M, Tookey AP. Premature delivery and mother-to-child HIV transmission: risk: benefit analysis of HAART in pregnancy. Abstract of the Sixteenth Conference of Retroviruses and Opportunistic Infections, Montreal. 2009; Abstract 927.
  • 32
    Fiore S., Newell LM, Trabattoni D, Thorne C, Gray L, Savasi V, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006;70:14350.
  • 33
    Fiore S, Ferrazzi E, Newell LM, Trabattoni D, Clerici M. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis 2007;195:9146. author reply 6–7.
  • 34
    WHO. Rapid HIV tests- Guidelines for use in HIV testing and counselling in resource constrained settings. 2004.
  • 35
    UNAIDS/WHO/UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. WHO Library Cataloguing-in-Publication Data. 2009.
  • 36
    Samuel MN, Srijayanth P, Dharmarajan S, Bethel J, Van Hook H, Jacob M, et al. Acceptance of HIV-1 education & voluntary counselling/testing by & seroprevalence of HIV-1 among, pregnant women in rural south India. Indian J Med Res 2007;125:4964.
  • 37
    Kalichman CS, Simbayi CL. HIV testing attitudes, AIDS stigma, and voluntary HIV counselling and testing in a black township in Cape Town, South Africa. Sex Transm Infect 2003;79:4427.
  • 38
    Matovu KJ, Gray HR, Makumbi F, Wawer JM, Serwadda D, Kigozi G, et al. Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS 2005;19:50311.
  • 39
    Pignatelli S, Simpore J, Pietra V, Ouedraogo L, Conombo G, Saleri N, et al. Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop Med Int Health 2006;11:3507.
  • 40
    Bajunirwe F, Muzoora M. Barriers to the implementation of programs for the prevention of mother-to-child transmission of HIV: a cross-sectional survey in rural and urban Uganda. AIDS Res Ther 2005;2:10.
  • 41
    Mkwanazi BN, Patel D, Newell LM, Rollins CN, Coutsoudis A, Coovadia MH, et al. Rapid testing may not improve uptake of HIV testing and same day results in a rural South African community: a cohort study of 12,000 women. PLoS ONE 2008;3:e3501.
  • 42
    Dahl V, Mellhammar L, Bajunirwe F, Bjorkman P. Acceptance of HIV testing among women attending antenatal care in south-western Uganda: risk factors and reasons for test refusal. AIDS Care 2008;20:74652.
  • 43
    Larsson CE, Waiswa P, Thorson A, Tomson G, Peterson S, Pariyo G, et al. Low uptake of HIV testing during antenatal care: a population-based study from eastern Uganda. AIDS 2009;23:19246.
  • 44
    Pai PN, Barick R, Tulsky PJ, Shivkumar VP, Cohan D, Kalantri S, et al. Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. PLoS Med 2008;5:e92.
  • 45
    Farquhar C, Kiarie NJ, Richardson AB, Kabura NM, John NF, Nduati WR, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr 2004;37:16206.
  • 46
    Homsy J, King R, Malamba SS, Opio C, Kalamya NJ, Mermin J, et al. The need for partner consent is a main reason for opting out of routine HIV testing for prevention of mother-to-child transmission in a rural Ugandan hospital. J Acquir Immune Defic Syndr 2007;44:3669.
  • 47
    Sarker M, Sanou A, Snow R, Ganame J, Gondos A. Determinants of HIV counselling and testing participation in a prevention of mother-to-child transmission programme in rural Burkina Faso. Trop Med Int Health 2007;12:147583.
  • 48
    Kizito D, Woodburn WP, Kesande B, Ameke C, Nabulime J, Muwanga M, et al. Uptake of HIV and syphilis testing of pregnant women and their male partners in a programme for prevention of mother-to-child HIV transmission in Uganda. Trop Med Int Health 2008;13:6802.
  • 49
    Msuya ES, Mbizvo ME, Hussain A, Uriyo J, Sam EN, Stray-Pedersen B. Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs. AIDS Care 2008;20:7009.
  • 50
    Kakimoto K, Kanal K, Mukoyama Y, Chheng VT, Chou LT, Sedtha C. Influence of the involvement of partners in the mother class with voluntary confidential counselling and testing acceptance for prevention of mother to child transmission of HIV programme (PMTCT programme) in Cambodia. AIDS Care 2007;19:3814.
  • 51
    Chandisarewa W, Stranix-Chibanda L, Chirapa E, Miller A, Simoyi M, Mahomva A, et al. Routine offer of antenatal HIV testing (“opt-out” approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. Bull World Health Organ 2007;85:84350.
  • 52
    Perez F, Zvandaziva C, Engelsmann B, Dabis F. Acceptability of routine HIV testing (“opt-out”) in antenatal services in two rural districts of Zimbabwe. J Acquir Immune Defic Syndr 2006;41:51420.
  • 53
    Creek LT, Ntumy R, Seipone K, Smith M, Mogodi M, Smit M, et al. Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. J Acquir Immune Defic Syndr 2007;45:1027.
  • 54
    Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K, et al. Evaluation of the PIMA Point-of-Care CD4 Analyzer in VCT Clinics in Zimbabwe. J Acquir Immune Defic Syndr 2010;55:17.
  • 55
    Kilewo C, Massawe A, Lyamuya E, Semali I, Kalokola F, Urassa E, et al. HIV counseling and testing of pregnant women in sub-Saharan Africa: experiences from a study on prevention of mother-to-child HIV-1 transmission in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2001;28:45862.
  • 56
    Horwood C, Rollins N, Vermaak K, Haskins L, Mzolo S, Phakathi S. KZN Impact 2009: An Evaluation of the Implementation of the PMTCT Programme in Six Districts in KwaZulu-Natal. Durban, South Africa: Centre for Rural Health, University of KwaZulu-Natal, 2009.
  • 57
    Fiscus AS, Pilcher DC, Miller CW, Powers AK, Hoffman FI, Price M, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007;195:41624.
  • 58
    McDonald C, Lambert J, Nayagam D, Welz T, Poulton M, Aleksin D, et al. Why are children still being infected with HIV? Experiences in the prevention of mother-to-child transmission of HIV in south London. Sex Transm Infect 2007;83:5963.
  • 59
    Moses ES, Tosswill J, Sudhanva M, Poulton M, Zuckerman M. HIV-1 seroconversion during pregnancy resulting in vertical transmission. J Clin Virol 2008;41:1523.
  • 60
    Struik SS, Tudor-Williams G, Taylor PG, Portsmouth DS, Foster JC, Walsh C, et al. Infant HIV infection despite “universal” antenatal testing. Arch Dis Child 2008;93:5961.
  • 61
    ACOG committe. ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2004;104:111924.
  • 62
    Tubiana R, Chenadec LJ, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the french perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50:58596.
  • 63
    Newell LM. Current issues in the prevention of mother-to-child transmission of HIV-1 infection. Trans R Soc Trop Med Hyg 2006;100:15.
  • 64
    Nesheim S, Jamieson JD, Danner PS, Maupin R, O’Sullivan JM, Cohen HM, et al. Primary human immunodeficiency virus infection during pregnancy detected by repeat testing. Am J Obstet Gynecol 2007;197:149 e1–5.
  • 65
    Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau MA, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Eng J Med 2000;343:98291.
  • 66
    Yeom SJ, Jun G, Chang Y, Sohn JM, Yoo S, Kim E, et al. Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods 2006;137:2927.
  • 67
    Black V, von Mollendorf EC, Moyes AJ, Scott EL, Puren A, Stevens SW. Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme. BJOG 2009;116:18058.
  • 68
    Matemo D, Kinuthia J, John F, Chung M, Farquhar C, John-Stewart G, et al. Indeterminate rapid HIV-1 test results among antenatal and postnatal mothers. Int J STD AIDS 2009;20:7902.
  • 69
    Bhore VA, Sastry J, Patke D, Gupte N, Bulakh MP, Lele S, et al. Sensitivity and specificity of rapid HIV testing of pregnant women in India. Int J STD AIDS 2003;14:3741.
  • 70
    WHO. Guidance on provider-initiated HIV testing and counselling in health facilities. http://www.who.int/hiv/pub/vct/pitc/en/ . 2007.
  • 71
    Jamieson JD, Clark J, Kourtis PA, Taylor WA, Lampe AM, Fowler GM, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007;197(Suppl. 3):S2632.
  • 72
    Doh SA. Policy and Guidelines for the Implementation of the PMTCT Programme. http://www.doh.gov.za/docs/policy-f.html . 2008.
  • 73
    NICE. Antenatal care: routine care for the healthy pregnant woman. http://www.guidance.nice.org.uk/CG62/Guidance/pdf/English . 2008.
  • 74
    BHIVA. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452502.
  • 75
    Jamieson JD, Cohen HM, Maupin R, Nesheim S, Danner PS, Lampe AM, et al. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience. Am J Obstet Gynecol 2007;197(Suppl. 3):S7282.
  • 76
    Jamieson JD, O’Sullivan JM, Maupin R, Cohen M, Webber PM, Nesheim S, et al. The challenges of informed consent for rapid HIV testing in labor. J Womens Health (Larchmt) 2003;12:88995.
  • 77
    Tan RK, Lampe AM, Danner PS, Kissinger P, Webber PM, Cohen HM, et al. Factors associated with declining a rapid human immunodeficiency virus test in labor and delivery. Matern Child Health J 2010; [Epub ahead of print 10 January 2010].
  • 78
    Rollins N, Little K, Mzolo S, Horwood C, Newell LM. Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening. AIDS 2007;21:13417.
  • 79
    Pilcher DC, Fiscus AS, Nguyen QT, Foust E, Wolf L, Williams D, et al. Detection of acute infections during HIV testing in North Carolina. N Eng J Med 2005;352:187383.
  • 80
    Priddy HF, Pilcher DC, Moore HR, Tambe P, Park NM, Fiscus AS, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007;44:196202.
  • 81
    Truong MH, Grant MR, McFarland W, Kellogg T, Kent C, Louie B, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:21937.
  • 82
    Karim SS, Mlisana K, Kharsany BA, Williamson C, Baxter C, Karim AQ. Utilizing nucleic acid amplification to identify acute HIV infection. AIDS 2007;21:6535.
  • 83
    WHO. HIV transmission through breastfeeding – a review of available evidence. http://www.whqlibdoc.who.int/publications/2008/9789241596596_eng.pdf . 2007.
  • 84
    HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study. AIDS 2001;15:76170.
  • 85
    Blanche S, Rouzioux C, Moscato LM, Veber F, Mayaux JM, Jacomet C, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Eng J Med 1989;320:16438.
  • 86
    Taha ET, Hoover RD, Kumwenda IN, Fiscus AS, Kafulafula G, Nkhoma C, et al. Late postnatal transmission of HIV-1 and associated factors. J Infect Dis 2007;196:104.
  • 87
    Borkowsky W, Krasinski K, Cao Y, Ho D, Pollack H, Moore T, et al. Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994;125:34551.
  • 88
    Jourdain G, Mary YJ, Coeur LS, Ngo-Giang-Huong N, Yuthavisuthi P, Limtrakul A, et al. Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. J Infect Dis 2007;196:162936.
  • 89
    Sperling SR, Shapiro ED, Coombs WR, Todd AJ, Herman AS, McSherry DG, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Eng J Med 1996;335:16219.
  • 90
    Dickover ER, Garratty ME, Herman AS, Sim SM, Plaeger S, Boyer JP, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599605.
  • 91
    Mmiro AF, Aizire J, Mwatha KA, Eshleman HS, Donnell D, Fowler GM, et al. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr 2009;52:329.
  • 92
    Mandelbrot L, Mayaux JM, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla L. et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:6617.
  • 93
    Gupta A, Gupte N, Patil S, Sambarey P, Khadse S, Kagal A., et al. Maternal TB is associated with increased risk of HIV mother-to-child transmission. CROI2010. 2010;Poster899.
  • 94
    Landesman HS, Kalish AL, Burns ND, Minkoff H, Fox EH, Zorrilla C, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Eng J Med 1996;334:161723.
  • 95
    The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:10359.
  • 96
    The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 – a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Eng J Med 1999;340:97787.
  • 97
    Rollins CN, Becquet R, Bland MR, Coutsoudis A, Coovadia MH, Newell LM. Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes. AIDS 2008;22:234957.
  • 98
    Leroy V, Newell LM, Dabis F, Peckham C, van de Perre P, Bulterys M, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. Lancet 1998;352:597600.
  • 99
    Coovadia MH, Rollins CN, Bland MR, Little K, Coutsoudis A, Bennish LM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007;369:110716.
  • 100
    Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai YW, Coovadia MH. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001;15:37987.
  • 101
    Bland MR, Becquet R, Rollins CN, Coutsoudis A, Coovadia MH, Newell LM. Breast health problems are rare in both HIV-infected and HIV-uninfected women who receive counseling and support for breast-feeding in South Africa. Clin Infect Dis 2007;45:150210.
  • 102
    Kourtis PA, Butera S, Ibegbu C, Beled L, Duerr A. Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis 2003;3:78693.
  • 103
    Cooper RE, Charurat M, Mofenson L, Hanson CI, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:48494.
  • 104
    Dorenbaum A, Cunningham KC, Gelber DR, Culnane M, Mofenson L, Britto P, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288:18998.
  • 105
    Townsend LC, Cortina-Borja M, Peckham SC, Tookey AP. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. BJOG 2008;115:107886.
  • 106
    Public Health Service Task Force. Public Health Service Task Force: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines . 2009.
  • 107
    BHIVA. British HIV Association guidelines for the treatment of HIV-1infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563608.
  • 108
    Grosch-Woerner I, Puch K, Maier FR, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008;9:613.
  • 109
    Lallemant M, Jourdain G, Le Coeur S, Mary YJ, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Eng J Med 2004;351:21728.
  • 110
    Fiore S, Newell LM, Thorne C. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004;18:9338.
  • 111
    Boer K, England K, Godfried HM, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010;11:36878.
  • 112
    Connor ME, Sperling SR, Gelber R, Kiselev P, Scott G, O’Sullivan JM, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Eng J Med 1994;331:117380.
  • 113
    Gingelmaier A, Eberle J, Kost PB, Bogner RJ, Hofmann J, Weissenbacher T, et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin Infect Dis 2010;50:8904.
  • 114
    Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet 2000;355:4515.
  • 115
    WHO. Feeding the non-breastfed child 6–24 months of age. http://www.who.int/nutrition/publications/feeding_non_breastfed_child.pdf . 2004.
  • 116
    Becquet R, Leroy V, Ekouevi KD, Viho I, Castetbon K, Fassinou P, et al. Complementary feeding adequacy in relation to nutritional status among early weaned breastfed children who are born to HIV-infected mothers: ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d’Ivoire. Pediatrics 2006;117:e70110.
  • 117
    Kuhn L, Aldrovandi MG, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Eng J Med 2008;359:13041.
  • 118
    Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet 1999;353:78692.
  • 119
    Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O., et al. 18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS 2001;15:7719.
  • 120
    Wiktor ZS, Ekpini E, Karon MJ, Nkengasong J, Maurice C, Severin TS, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet 1999;353:7815.
  • 121
    Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:117886.
  • 122
    Bhoopat L, Khunamornpong S, Lerdsrimongkol P, Sirivatanapa P, Sethavanich S, Limtrakul A, et al. Effectiveness of short-term and long-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission. J Acquir Immune Defic Syndr 2005;40:54550.
  • 123
    Guay AL, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795802.
  • 124
    Jackson BJ, Musoke P, Fleming T, Guay AL, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:85968.
  • 125
    Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:72535.
  • 126
    Arrive E, Newell LM, Ekouevi KD, Chaix LM, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007;36:100921.
  • 127
    Chi HB, Sinkala M, Stringer ME, Cantrell AR, Mtonga V, Bulterys M, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007;21:95764.
  • 128
    Lockman S, Shapiro LR, Smeaton ML, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Eng J Med 2007;356:13547.
  • 129
    Jourdain G, Wagner AT, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 2010;50:1397404.
  • 130
    Coffie AP, Ekouevi KD, Chaix LM, Tonwe-Gold B, Clarisse BA, Becquet R, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003–2006. Clin Infect Dis 2008;46:61121.
  • 131
    Stringer SJ, McConnell SM, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 2010;7:e1000233.
  • 132
    Wagner AT, Kress MC, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, et al. Detection of HIV-1-Drug-resistance in women following single-dose-nevirapine: comparison of plasma RNA versus cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010;48:155561.
  • 133
    Eshleman HS, Hoover RD, Hudelson ES, Chen S, Fiscus AS, Piwowar-Manning E, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006;193:47981.
  • 134
    Thior I, Lockman S, Smeaton ML, Shapiro LR, Wester C, Heymann JS, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006;296:794805.
  • 135
    Victora C. Infection and disease: the impact of early weaning. Food Nutr Bull 1996;17:3906.
  • 136
    Victora GC, Smith GP, Vaughan PJ, Nobre CL, Lombardi C, Teixeira MA, et al. Evidence for protection by breast-feeding against infant deaths from infectious diseases in Brazil. Lancet 1987;2:31922.
  • 137
    Yoon WP, Black ER, Moulton HL, Becker S. Effect of not breastfeeding on the risk of diarrheal and respiratory mortality in children under 2 years of age in Metro Cebu, The Philippines. Am J Epidemiol 1996;143:11428.
  • 138
    Jones G, Steketee WR, Black ER, Bhutta AZ, Morris SS. How many child deaths can we prevent this year? Lancet 2003;362:6571.
  • 139
    Nicoll A, Williams A. Breast feeding. Arch Dis Child 2002;87:912.
  • 140
    Shapiro R. A randomized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child HIV transmission among breastfeeding women in Botswana (The Mma Bana Study). http://www.ias2009.org/pag/Abstracts.aspx?AID=3821. 2009;Presented at the 5th IAS Conference on HIV pathogenesis, treatment and prevention, 19–22 July 2009, Cape Town, South Africa.
  • 141
    Kilewo C. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers prophylactically with triple antiretroviral therapy in Dar es Salaam, Tanzania – the MITRA PLUS study. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract no TUAX101. 2007.
  • 142
    Thomas T, Masaba R, Ndivo R. PMTCT of HIV-1 among breast-feeding women using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003–2007. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3–6 February 2008, Abstract 45aLB. 2008.
  • 143
    WHO. Impact of highly active anti retroviral therapy during pregnancy and breastfeeding on mother-to-child-transmission of HIV and mother’s health: The Kesho Bora Study. http://www.who.int/reproductivehealth/topics/rtis/kesho_bora_brief/en/2009;Presented at the 5th IAS Conference on HIV pathogenesis, treatment and prevention, 19–22 July 2009, Cape Town, South Africa.
  • 144
    Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008;48:31523.
  • 145
    Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008;372:30013.
  • 146
    Kumwenda IN, Hoover RD, Mofenson ML, Thigpen CM, Kafulafula G, Li Q, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Eng J Med 2008;359:11929.
  • 147
    Vyankandondera J, Luchters S, Hassink E. Reducing the risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study). 2nd International AIDS Conference on HIV Pathogenesis and Treatment, Paris, France, 13–17 July 2003, Abstract LB7. 2003.
  • 148
    Taha ET, Kumwenda IN, Gibbons A, Broadhead LR, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003;362:11717.
  • 149
    Mofenson ML. Antiretroviral prophylaxis to reduce breast milk transmission of HIV type 1: new data but still questions. J Acquir Immune Defic Syndr 2008;48:23740.
  • 150
    Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009;4:e4096.
  • 151
    Lidstrom J, Li Q, Hoover RD, Kafulafula G, Mofenson ML, Fowler GM, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010;24:3816.
  • 152
    ANRS. Comparison of efficacy and safety of infant peri-exposure prophylaxis with lopinavir/ritonavir versus lamivudine to prevent HIV-1 transmission by breastfeeding. http://clinicaltrials.gov/ct2/show/NCT00640263 .
  • 153
    Chasela C. Both maternal HAART and daily infant nevirapine (NVP) are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breastfeeding, Antiretroviral and Nutrition (BAN) Study. http://ias2009.org/pag/Abstracts.aspx?AID=3751. 2009;Presented at the 5th IAS Conference on HIV pathogenesis, treatment and prevention, 19–22 July 2009, Cape Town, South Africa.
  • 154
    Fowler GM. Promoting maternal and infant survival everywhere. http://www.impaactgroup.org/introduction-p1077-promise-training .
  • 155
    WHO. HIV and infant feeding: revised principles and recommendations. RAPID ADVICE. WHO Library Cataloguing-in-Publication Data. 2009.
  • 156
    Quigley AM, Kelly JY, Sacker A. Breastfeeding and hospitalization for diarrheal and respiratory infection in the United Kingdom Millennium Cohort Study. Pediatrics 2007;119:e83742.
  • 157
    Kuhn L, Reitz C, Abrams JE. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009;21:8393.
  • 158
    Kuhn L, Sinkala M, Kankasa C, Semrau K, Kasonde P, Scott N, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS ONE 2007;2:e1363.
  • 159
    Su LL, Chong SY, Chan HY, Chan SY, Fok D, Tun TK, et al. Antenatal education and postnatal support strategies for improving rates of exclusive breast feeding: randomised controlled trial. BMJ 2007;335:596.
  • 160
    Bhandari N, Bahl R, Mazumdar S, Martines J, Black ER, Bhan KM. Effect of community-based promotion of exclusive breastfeeding on diarrhoeal illness and growth: a cluster randomised controlled trial. Lancet 2003;361:141823.
  • 161
    Bland MR, Little EK, Coovadia MH, Coutsoudis A, Rollins CN, Newell LM. Intervention to promote exclusive breast-feeding for the first 6 months of life in a high HIV prevalence area. AIDS 2008;22:88391.
  • 162
    Becquet R, Ekouevi KD, Viho I, Sakarovitch C, Toure H, Castetbon K, et al. Acceptability of exclusive breast-feeding with early cessation to prevent HIV transmission through breast milk, ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 2005;40:6008.
  • 163
    The Kesho Bora Study Group. Triple-antiretroviral prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya, and South Africa. http://www.who.int/reproductivehealth/topics/rtis/kesho_bora_brief/en/Presented at the 5th IAS Conference on HIV pathogenesis, treatment and prevention, 19–22 July 2009, Cape Town, South Africa. 2009.
  • 164
    Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris RD, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004;189:215466.
  • 165
    Stringer ME, Ekouevi KD, Coetzee D, Tih MP, Creek LT, Stinson K, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010;304:293302.
  • 166
    Rollins CN, Dedicoat M, Danaviah S, Page T, Bishop K, Kleinschmidt I, et al. Prevalence, incidence, and mother-to-child transmission of HIV-1 in rural South Africa. Lancet 2002;360:389.
  • 167
    Mate SK, Bennett B, Mphatswe W, Barker P, Rollins N. Challenges for routine health system data management in a large public programme to prevent mother-to-child HIV transmission in South Africa. PLoS ONE 2009;4:e5483.
  • 168
    WHO. Global strategy for the prevention and control of sexually transmitted infections: 2006–2015: breaking the chain of transmission. http://www.who.int/reproductivehealth/publications/rtis/9789241563475/en/ . 2007.
  • 169
    Freedman PL, Waldman JR, de Pinho H, Wirth EM, Chowdhury MA, Rosenfield A. Transforming health systems to improve the lives of women and children. Lancet 2005;365:9971000.
  • 170
    WHO. Guidance on global scale-up of the prevention of mother-to-child transmission of HIV. WHO Library Cataloguing-in-Publication Data; 2007.
  • 171
    The Kesho Bora Study Group. Impact of triple-ARV prophylaxis during pregnancy and breastfeeding compared with short-ARV prophylaxis for MTCT prevention on maternal disease progression: interim results. Presented International AIDS Conference, Vienna, 22 July 2010 Reference: ThLBB105. 2010.
  • 172
    Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. Lancet 1999;353:9012.
  • 173
    FDA. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173947.htm . 2001.
  • 174
    Nightingale LS. From the food and drug administration. JAMA 1998;280:1472.
  • 175
    Chersich FM, Urban FM, Venter WF, Wessels T, Krause A, Gray EG, et al. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006;3:11.
  • 176
    Public Health Service Task Force: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://www.AIDSinfo.nih.gov . 2008.
  • 177
    Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006;7:25560.
  • 178
    Baylor SM, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004;35:5389.
  • 179
    Dinsmoor JM, Forrest TS. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002;10:18791.
  • 180
    Taha ET, Kumwenda IN, Hoover RD, Fiscus AS, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004;292:2029.